- Home
- OXSQ vs GLSI Comparison
OXSQ vs GLSI Comparison
Compare OXSQ & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OXSQ
- GLSI
- Stock Information
- Founded
- OXSQ 2003
- GLSI 2006
- Country
- OXSQ United States
- GLSI United States
- Employees
- OXSQ N/A
- GLSI N/A
- Industry
- OXSQ Blank Checks
- GLSI Biotechnology: Pharmaceutical Preparations
- Sector
- OXSQ Finance
- GLSI Health Care
- Exchange
- OXSQ Nasdaq
- GLSI Nasdaq
- Market Cap
- OXSQ 178.7M
- GLSI 149.5M
- IPO Year
- OXSQ N/A
- GLSI 2020
- Fundamental
- Price
- OXSQ $2.18
- GLSI $11.23
- Analyst Decision
- OXSQ
- GLSI Strong Buy
- Analyst Count
- OXSQ 0
- GLSI 1
- Target Price
- OXSQ N/A
- GLSI $39.00
- AVG Volume (30 Days)
- OXSQ 695.4K
- GLSI 54.0K
- Earning Date
- OXSQ 11-04-2025
- GLSI 08-14-2025
- Dividend Yield
- OXSQ 19.31%
- GLSI N/A
- EPS Growth
- OXSQ N/A
- GLSI N/A
- EPS
- OXSQ N/A
- GLSI N/A
- Revenue
- OXSQ $40,243,556.00
- GLSI N/A
- Revenue This Year
- OXSQ N/A
- GLSI N/A
- Revenue Next Year
- OXSQ N/A
- GLSI N/A
- P/E Ratio
- OXSQ N/A
- GLSI N/A
- Revenue Growth
- OXSQ N/A
- GLSI N/A
- 52 Week Low
- OXSQ $2.14
- GLSI $8.06
- 52 Week High
- OXSQ $2.99
- GLSI $15.50
- Technical
- Relative Strength Index (RSI)
- OXSQ 36.86
- GLSI 46.72
- Support Level
- OXSQ $2.18
- GLSI $11.12
- Resistance Level
- OXSQ $2.22
- GLSI $13.00
- Average True Range (ATR)
- OXSQ 0.03
- GLSI 0.63
- MACD
- OXSQ -0.00
- GLSI -0.06
- Stochastic Oscillator
- OXSQ 14.29
- GLSI 26.56
About OXSQ Oxford Square Capital Corp.
Oxford Square Capital Corp is a closed-end, non-diversified management investment company with a focus is to seek an attractive risk-adjusted total return by investing in corporate debt securities and collateralized loan obligation (CLO) structured finance investments that own corporate debt securities. its capital is generally used by its corporate borrowers to finance organic growth, acquisitions, recapitalizations, and working capital. The group invests in various industries such as Structured Finance, IT Consulting, Business Services, Utilities, Software, Healthcare, Telecommunication Services, Plastics Manufacturing and Diversified Insurance.
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.